Ticker: ABVX

Abivax

Biotech Healthcare Biotechnology

Price 125.70

Reco Sell Potential 39 Risk 76 Updated 2026-07-27

Official website

Forecast impact

positive

Target +43.2% target fill 69.8%

Reaction D5 pending · D10 pending fresh confirmed · market trust

Impact Potential +6 · Risk -3 valid until 2026-08-23

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Abivax (ABVX) operates in the healthcare sector, focusing on the development of innovative therapies for inflammatory and viral diseases. Its core products include ABX464, aimed at treating ulcerative colitis and HIV. The company primarily generates revenue through research and development partnerships and potential future product sales. Abivax is currently in clinical trial phases, with no commercialized products yet contributing to revenue.

Investment Profile

The investment profile of Abivax is more aligned with growth investors, given its focus on developing new therapies and the potential for future revenue generation. However, the high risk associated with its current financial performance and lack of profitability may deter conservative investors. The stock may appeal to those with a higher risk tolerance looking for long-term opportunities.

Category: Biotech Sector: Healthcare Industry: Biotechnology Investment style: Growth Horizon: Medium-term Company type: Small Cap

Fundamental metrics (experimental) Updated: 2026-07-22

EPS (TTM) — earnings per share for the last 12 months, $: -5.84
Revenue QoQ — quarter-over-quarter revenue growth: -200.0%
EPS surprise: 24.8%
20d volatility: 8.8%

AI recommendation changes

Date	Before	After	Reason
2026-07-23	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-07-16	Sell	Hold	High risk with uncertain fundamentals and mixed momentum.
2026-07-09	Hold	Sell	Weak fundamentals and negative momentum raise significant risk.
2026-07-01	Sell	Hold	High volatility with uncertain fundamentals and performance.
2026-06-03	Hold	Sell	scenario_deterioration
2026-05-30	Sell	Hold	Weak fundamentals with recent positive momentum.
2026-05-08	—	Sell	Weak fundamentals and negative momentum raise significant risks.
2026-05-08	Sell	Sell	Компания Abivax демонстрирует высокую волатильность и отрицательные показатели EPS, что указывает на риски. Однако недавний рост за 60 и 120 дней может свидетельствовать о потенциальном восстановлении.
2026-05-01	Hold	Sell	Компания Abivax демонстрирует высокую волатильность и негативные финансовые показатели, такие как отрицательный EPS и резкое снижение выручки. Рекомендуется удерживать акции до получения более ясных сигналов о восстановл
2026-04-23	Sell	Hold	Компания демонстрирует положительную динамику за последние 120 дней, однако отрицательный EPS и резкое снижение выручки вызывают опасения. Рекомендуется удерживать акции до получения более ясных сигналов о восстановлении
2026-04-14	Hold	Sell	Компания показывает отрицательные результаты по EPS и значительное снижение выручки, что указывает на высокие риски. Текущая цена также колебалась, что может свидетельствовать о нестабильности.
2026-04-02	Sell	Hold	Компания демонстрирует высокую волатильность и негативные финансовые показатели, такие как отрицательный EPS и значительное снижение выручки. Тем не менее, за последние 120 дней наблюдается рост, что может свидетельствов
2026-03-25	Hold	Sell	scenario_deterioration
2026-03-11	Sell	Hold	Компания показывает значительные колебания цен и отрицательные показатели EPS, что указывает на высокие риски. Однако недавний рост на 27.65% за 120 дней может свидетельствовать о потенциальном восстановлении.
2026-03-03	Hold	Sell	Компания показывает значительное снижение выручки и отрицательный EPS, что указывает на финансовые трудности. Текущая волатильность и негативная динамика цены акций также свидетельствуют о высоком риске для инвесторов.
2026-01-27	—	Hold	Компания демонстрирует сильный рост за последние 120 дней, однако недавние колебания цен и отсутствие данных о прибыли и выручке создают неопределенность. Рекомендуется удерживать акции до получения более ясной финансово

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-07-24	Morgan Stanley	Target Raised	132 → 180	128.635
2026-07-09	Piper Sandler	Target Raised	165 → 175	138.54
2026-07-02	Truist Financial	Target Raised	135 → 155	132.56
2026-06-30	Jefferies	Rating Upgraded	— → 158	133.26
2026-06-30	BTIG	Target Raised	— → 175	96.15
2026-06-03	Wolfe Research	Target Lowered	176 → 136	89.72
2026-06-02	Truist Financial	Target Lowered	140 → 135	77.82
2026-06-02	Morgan Stanley	Target Lowered	145 → 132	129.69
2026-06-02	Wedbush	Update	— → 90	129.69
2026-06-02	Jefferies	Update	— → 90	129.69
2026-02-24	Wedbush	Update	— → 110	132.91
2026-01-09	Morgan Stanley	Target Raised	101 → 145	116.97
2026-01-08	BTIG	Target Raised	120 → 150	126.48
2026-01-08	Oppenheimer	Update	— → 131	126.48
2025-12-18	Guggenheim	Target Raised	150 → 175	117.235
2025-12-16	Piper Sandler	Target Raised	112 → 142	110.98
2025-11-24	Truist Financial	Update	— → 140	119.12
2025-11-05	Wolfe Research	Update	— → 176	99.61
2025-10-13	Barclays	Update	— → 142	93.77
2025-10-10	Guggenheim	Target Raised	— → 150	90.61

News Page 1 of 1

Abivax Secures $920 Million Funding to Prepare for Independent U.S. Launch of Bowel Disease Drug, CEO Marc de Garidel Tells CNBC

07/10/2026, 03:36 AM business announcement biotech Abivax

Abivax has successfully raised $920 million, enabling it to independently pursue the U.S. launch of its bowel disease drug, obefazimod, without relying on a potential acquisition. This funding positions the company to finance operations through 2029 and address recent investor concerns regarding the drug's safety and efficacy.

Analysts Jefferies upgraded Abivax (ABVX) to Buy and raised target price to $158 (upside +18%) following positive ulcerative colitis treatment data

07/01/2026, 03:36 AM investing rating_growth Analysts: analysts, Jefferies Abivax

Jefferies has upgraded Abivax to a buy rating following positive data on its ulcerative colitis treatment, indicating potential for further stock growth.

Stocks Making Significant Moves Midday: AeroVironment Reports Earnings Beat, Abivax Shares Surge 40%

06/30/2026, 10:37 AM review Watts Water Technologies KLA Corp SolarEdge Technologies Air Products and Chemicals Abivax Applied Materials Digital Realty AeroVironment Zimmer Biomet

Midday trading saw significant movements in various stocks, particularly in the semiconductor sector, which is on track for a record quarter, and biotech firm Abivax, which experienced a substantial surge following positive treatment data.

Abivax (ABVX) shares surge 25% following positive data on experimental bowel disease treatment

06/30/2026, 12:35 AM business stock_growth biotech Abivax

Abivax's stock surged 25% following the release of new clinical trial data for its experimental drug obefazimod, which alleviated concerns over cancer risks associated with the treatment. This rebound is significant for investors, as it indicates renewed confidence in the company's prospects after a prior steep decline.

Abivax (ABVX) Shares Plunge Over 30% Following Update on Bowel Disease Drug Trial

06/02/2026, 12:31 AM stock_drop biotech Abivax

Abivax is strategically planning to raise funds following the release of crucial trial data, indicating its intent to remain independent amid ongoing takeover speculation, which has significantly influenced its stock performance.